Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration-Reference-Cited by-同舟云学术

Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration

Published:2015-09-01 Issue:4 Volume:49 Page:268-275
ISSN:1869-3474
Container-title:Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Nucl Med Mol Imaging

Author:

Son Seung Hyun,Lee Sang-Woo,Jung Ji-hoon,Kim Choon-Young,Kim Do-Hoon,Jeong Shin Young,Ahn Byeong-Cheol,Lee Jaetae

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1007/s13139-015-0348-y.pdf

Reference28 articles.

1. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocr Metab. 2003;88:1433–41.

2. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105–12.

3. Dietlein M, Busemeyer S, Kobe C, Schmidt M, Theissen P, Schicha H. Recombinant human TSH versus hypothyroidism. cost-minimization-analysis in the follow-up care of differentiated thyroid carcinoma. Nuklearmedizin. 2010;49:216–24.

4. Heinzel A, Kley K, Mueller HW, Hautzel H. A comparison of rh-TSH and thyroid hormone withdrawal in patients with differentiated thyroid cancer: preliminary evidence for an influence of age on the subjective well-being in hypothyroidism. Horm Metab Res. 2012;44:54–9.

5. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20:173–9.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review;Iranian Journal of Pharmaceutical Research;2022-05-14

2. The value of serum thyroglobulin alteration after ultrasonography‐guided fine‐needle biopsy of suspicious cervical lymph nodes in the diagnosis of metastasis in patients with differentiated thyroid cancer;International Journal of Clinical Practice;2021-05-09

3. Serum thyroglobulin elevation after needle aspiration of the lymph nodes: the predictive value for detecting metastasis in papillary thyroid cancer patients – a pilot study;Medicine;2019-08

4. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer;PLOS ONE;2018-08-17

5. Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?;Acta Otorhinolaryngologica Italica;2018-06